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1. Introduction 
GD2 ganglioside is an important example of tumour-associated carbohydrate antigens. Over 
expression of the GD2 ganglioside is a hallmark of neuroblastoma, while its expression on 
normal cells is restricted. The antigen is stably expressed on cells of the tumour, and 
retained during a therapy of the disease (Kramer et al., 2001). The facts allow to use its 
presence to diagnose neuroblastoma, monitor response to treatment, and target the tumour 
cells (Navid et al., 2010; Reuland et al., 2001; Swerts et al., 2005). 
 
 
Fig. 1. A schematic representation of the GD2 ganglioside structure (abbreviations: Glc, 
glucose; Gal, galactose; GalNAc,, N-acetylgalactosamine; Sia, sialic acid). 
The GD2 ganglioside is a member of glycolipids, compounds that are commonly present in 
outer plasma membrane of animal cells. The GD2 ganglioside is a polar molecule. The 
hydrophilic part is made from a carbohydrate chain, charged due to the presence of two 
sialic acid residues, and exposed to cell outside. The second part of the molecule is 
hydrophobic in nature, functions as a membrane anchor, and it is formed by a ceramide, 
fatty acid sphingosine (Fig. 1). Gangliosides were shown to be involved in many aspects of 
cancer biology. Changes in their expression may influence cell signalling pathways, 
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morphology, proliferation, invasiveness, and tumour progression, as shown in cell cultures 
and in vivo (Ruan et al., 1999; Yoshida et al., 2001). The gangliosides are shed from cell 
membranes, and are present in sera of cancer patients (Czaplicki et al., 2009). 
Immunomodulating activities of the GD2 ganglioside were also described (Ladish et al., 
1994). The GD2 ganglioside allows for successful targeting of neuroblastoma with 
monoclonal antibodies binding the tumour-associated carbohydrate antigen (Kushner et al., 
2011; Yu et al., 2011). Novel active approaches targeting the GD2 ganglioside are under 
development to improve weak-immunogenicity of the self antigen, including GD2 
ganglioside-KLH conjugates, anti-idiotypes, and peptide mimetics (Foon et al., 2000; 
Chapman et al., 2000,). In the chapter we review approaches to improve immunogencity of 
the GD2 ganglioside, with emphasis on application of peptide mimetics. 
2. Molecular mimicry phenomenon 
A molecular mimicry phenomenon relies on similarities between chemically diverse 
molecules, i.e., a surrogate and an original antigen (epitope) in the context of their ability to 
bind to a given target. Numerous data highlight that peptides, which are small molecules, 
consisting of amino acids linked with the peptide bond in a linear order, can be 
carbohydrate mimetics, inhibitors of carbohydrate-protein interactions, but also 
immunogens. Such peptides can be isolated from phage-displayed peptide libraries, 
synthetic libraries constructed with combinatorial chemistry, or rationally designed (Aina et 
al., 2007; Johnson & Pinto, 2008; Pande et al., 2010). 
Antigenicity of peptide mimetics relies on their ability to bind to receptors, such as 
antibodies, enzymes, or lectins. Their reactivity can be measured with several assays (ELISA, 
Western blot). Additional competition tests for binding between mimicking peptides and 
the natural ligand can prove, if the peptides can bind at or near the antigen binding site. 
Further studies often include evaluation of residues critical for binding, their replacement, 
shortening or extension of the peptide length. All of these can help to characterise the 
binding. Moreover, structures of free and the receptor-bound mimetics can be compared 
experimentally, or with application of computational docking (Huang et al., 2011). As a 
result, lead compounds can be identified, and further developed to replace natural antigens 
in diagnostic assays, and in therapy (Deroo & Muller, 2001). 
The nature of the peptide-carbohydrate mimicry is extensively studied, as more examples 
are reported (Jonson & Pinto, 2008). On the molecular level, structural mimicry can be 
distinguished, if a peptide can replicate three-dimensional (3D) interactions made by the 
carbohydrate with the target binding site. The contacts are mediated due to a certain 
arrangement of functional groups. The interaction does not require for such a peptide to 
have a similar 3D shape, as the mimicked carbohydrate. Instead, it may be facilitated by a 
high degree of flexibility that characterises peptides. This can allow for an arrangement of 
peptide functional groups within the target binding site that is critical for the structural 
mimicry to occur. Another type of interactions, namely functional mimicry, takes place, 
when a peptide does not interact with the binding site of the target in the same way, as the 
mimicked carbohydrate. Here, the peptide binds engaging different set of residues at the 
binding site of the target. A peptide can also made contacts at a distinct site, as compared to 
the carbohydrate. Based on the extensive data published, one can conclude that there is no 
consistent or preferred mechanism by which peptides mimic carbohydrates. Moreover, 
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mixed types of the above described binding modes are often observed (Agostino et al., 2011, 
see also examples in the paragraph 4.3). 
Immunological mimicry may be desired, if the use of an original antigen in vaccine 
formulation is not the best suited. Immunologically functional mimetics (mimotopes) induce 
antibodies that cross react with the original antigen. Mimotopes can be useful, if a natural 
antigen is unknown, hard to purify, or synthesise, or weakly immunogenic (Popkov et al., 
2000; Tai et al., 1985). This also applies in general to carbohydrates that due to chirality are 
costly, and uneasy in their synthesis. Here, application of carbohydrate mimicking peptides 
as surrogates is justified, and often possible (Fleuridor et al., 2001; Kieber-Emmons et al., 
2000). However, discrepancies between antigenicity and immunogenicity of mimicking 
peptides are often observed (El Kasmi et al., 1999; Willers et al., 1999). Many antigenic 
peptides isolated with antibodies are not immunogenic, because they do not bind the same 
paratope, as the natural epitope. Based on the published data, it is still unclear to what 
extent antibody bound conformation of a peptide, or conformation of the peptide in solution 
is related to immunogenicity (Theillet et al., 2009). It is known, that biologically functional 
mimicry can be affected for example by the sequence, flexibility of free peptides, a phage 
environment, conjugation to carrier protein, expression on a protein scaffold, a fit induced 
during interactions between the selecting antibody and the mimic. 
Many features of peptides can justify their use in place of carbohydrates. The methodology 
of their synthesis is well established, and can be automatic. The peptide structure can be 
modified in order to delay their degradation in vivo. Although, peptides in general are 
highly flexible, there are approaches to restrain their conformation through introduction of 
structure constrains, or their presentation as a part of a larger protein scaffold. More 
importantly, peptides are thymus dependent antigens, and therefore attractive surrogates of 
generally weakly immunogenic carbohydrates. Furthermore, peptides can be conjugated to 
carrier proteins, and even transferred to a DNA sequence, depending on the delivery 
schedule, and types of the immune response desired. The molecular mimicry lays a basis for 
application of anti-idiotypic antibodies, and peptide mimetics of the GD2 ganglioside 
isolated from phage displayed-libraries, as novel candidates to induce immune responses 
against neuroblastoma. 
3. Anti-idiotypic antibodies to target the GD2 ganglioside 
Monoclonal antibodies are effective means to fight cancer. The molecules can affect 
signalling pathways critical for malignancy, trigger, or enhance anti-tumour immune 
responses (Weiner et al., 2009). Monoclonal antibodies binding the GD2 ganglioside, e.g., the 
14.G2a (mouse monoclonal antibody, IgG2a), the 3F8 (mouse monoclonal antibody, IgG3), 
the ch14.18 (chimeric antibody consisting of variable regions of the murine monoclonal 
antibody 14.18, and the constant regions of human IgG-) were tested in clinical trials 
(Modak & Cheung, 2010). Recently, treatment with the ch14.18 was shown to significantly 
improve event-free survival, and overall survival in a phase III clinical trial in patients with 
high risk neuroblastoma (Yu et al., 2011). Moreover, approaches to reduce the treatment-
associated pain are being developed (Kushner et al., 2011; Sorkin et al., 2010). On the one 
side, HAMA (human anti-mouse antibody), and HACA (human anti-chimeric antibody) 
responses can be induced in patients after administration of antibodies, and if acute unable 
the further treatment. On the other side, induction of idiotypic network measured by 
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presence of anti-anti-idiotypic antibodies and binding the GD2 ganglioside antibodies, 6 and 
11 months after the 3F8 administration, was associated with long-term survival of patients 
with stage 4 neuroblastoma (Cheung et al., 2000). 
Three major types of anti-Ig molecules can be induced, based on which part of the antibody 
they will recognize, i.e., anti-isotypic, anti-allotypic, anti-idiotypic antibodies. Isotypic 
determinants consist of epitopes specific to one of five heavy chains (H), or one of two light 
chains (L) of antibodies. Allotypic determinants reflect allelic polymorphism existing in 
various regions of Ig constant genes. Thus, a particular isotype of an antibody common to 
members of a species may exist in several allogenic forms. Additionally, each Ig molecule 
has a unique (not-shared by any other member of the species) relatively minor differences 
that are defined by the hypervariable sequences in the variable region (i.e., antigen binding 
region). The collection of such unique determinants on a given Ig defines its idiotypes. It is 
suggested that network of anti-idiotypic antibodies may have a physiological function by 
regulating immune responses (Mak & Saunders, 2006). 
Anti-idiotypic antibodies binding specific paratopes can be induced with anti-GD2 
ganglioside antibodies (termed Ab1). Some anti-idiotypic antibodies can be used as 
surrogate antigens in immunizations to target the GD2 ganglioside. Variable regions of such 
anti-idiotypic antibodies (Ab2) may “immunologically resemble” the GD2 ganglioside, yet 
are not identical with the glycolipid. They react with the Ab1 antibody, and upon 
administration induce anti-anti-idiotypic antibodies (Ab3), also specific toward the GD2 
ganglioside (Ab1’) (Bhattacharya-Chatterjee et al., 2000; Saleh et al., 1993). 
The first anti-idiotypic antibody for neuroblastoma, used in clinical trials, was the 
monoclonal anti-idiotypic antibody for the 3F8, A1G4. In the phase I study in relapsed or 
high risk patients, administration of the anti-idiotype intravenously (i.v.) at 0.1, 0.3, 1 mg/kg 
for a total of 10 doses, induced anti-GD2 ganglioside antibody responses at all doses tested. 
No dose limiting toxicities (DLTs) were observed (Modak & Cheung, 2007 as cited in Modak 
& Cheung, 2010). 1A7 is yet another anti-idiotypic antibody. It was raised against the 14.G2a 
antibody. The 1A7 was tested in melanoma patients. 47 advanced melanoma patients 
received 1, 2, 4, 8-mg doses of the 1A7 mixed with QS-21 adjuvant (100 g), subcutaneously 
(s.c.), weekly for 4 weeks and then monthly until disease progression. In 40 out of 47 
patients that continued on study beyond 3 months, anti-GD2 ganglioside antibody 
responses were detected. In 20 patients the antibody concentrations ranged from 34-240 
g/ml. The responses were predominately IgG. There was no additional toxicity, such as 
abdominal pain. Authors concluded that although objective responses had been minimal, 
the approach should be tested in prospective randomised trials to further investigate 
possible favourable impact on disease progression (Foon et al., 2000). 
Zeytin et al. constructed DNA vaccine (pc1A7VHLnVL) encoding secreted form of the 
single chain variable fragment of the 1A7 (1A7scFV). Intramuscular injection of the DNA 
vaccine to mice induced both antibodies against the 1A7 antibody, and against the GD2 
ganglioside. However, no cellular immune responses were observed (Zeytin et al., 2000). On 
the contrary, GD2 ganglioside specific delayed-type hypersensitivity reactions (DTH) to the 
challenge with syngeneic GD2-positive melanoma cells D142.34 were induced by s.c. 
injection of mouse anti–idiotypic antibody TA412G Cl1 with complete Freund adjuvant in 
C57BL/6 mice, but not in in C57BL/6 CD4-/- mice. This suggested involvement of CD4+ T 
cells in the observed DTH reactions. Additionally, 3 out of 6 of anti-idiotypic antibodies 
(TA17A Cl2, TA412G Cl1, TB310B Cl1), precipitated by alum and administered to rabbits, 
induced IgG antibodies binding GD2 ganglioside positive melanoma WM115, and glioma 
251 MG cells (Basak at al., 2003). 
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4. Generation of peptide mimetics of the GD2 ganglioside 
Peptide displayed on bacteriophages, plasmids, polysomes, and various types of synthetic 
peptide libraries are invaluable sources of new ligands. They can be further tested as 
therapeutic leads, and therefore have a potential commercial value. In the following 
chapters, the technology of screening of peptide libraries based on filamentous 
bacteriophage display will be characterised. This will be followed by review of currently 
undertaken approaches to generate peptides mimicking the GD2 ganglioside. 
4.1 The filamentous bacteriophage life cycle 
The phage display is a powerful and challenging method to study interactions of proteins with 
other molecules including peptides, nucleic acids, and carbohydrates. Generally, the technique 
applies filamentous bacteriophages of the genus Inovirus (M13, fd, f1) infecting Escherichia coli, 
although other viral species, i.e., T4,  could be employed for peptide display. 
The wild filamentous viruses are rod-like structures, 930 nm in length, and 6.5 nm in diameter. 
Their protein capsid is mainly build of a small protein, the major coat protein p8, which is 
present in 2700 copies, and covers like a cylinder a circular single-stranded DNA genome. The 
DNA is build of 6400 bases, and encodes for eleven genes. At one end of the virion, there are 
five copies of each of p3 and p6 proteins, and the other end contains five copies of each of p7 
and p9 proteins. The filamentous phages infect male E. coli bacteria that have F pilus, made of 
subunits of pilin protein. The structure interacts with the p3 protein in the first step of 
infection. The further steps of the life cycle involve amplification of viral ssDNA, which is 
mediated by viral proteins p2, p5, p10 and host bacterium proteins. A double stranded circular 
DNA called a replicative form (RF) arises as an intermediate in the process. The minus strand 
of the RF form is used for transcription. Numerous copies of the viral ssDNA, covered with 
dimers of the p5 protein are produced as a result of the replication. This induces collapse of the 
DNA to a rod, leaving only the packaging signal exposed. 
The viral proteins that build the capsid, as well as proteins p4, p1, p11 are synthesised, and 
then embedded in bacterial membranes. The p4, p1, p11 proteins form sites (channels) in the 
bacterial envelope which bring cytoplasmic and outer membranes in a close contact. Here, a 
process of assembly of new viral particles takes place. The filamentous phages do not kill 
the infected bacteria, but slow the ratio of bacterial growth by half. The assembly process 
allows packing of all the capsid protein, integrated to the cytoplasmic membrane, around 
the DNA extruding from the cytoplasm. The end that leaves first the bacterium contains the 
p7 and the p9 protein, interacting with the packaging signal. The process of exchange of the 
p5 to the p8 continues till the end of the DNA is reached. Then, the p3 and the p6 are added, 
and a newly formed bacteriophage particle is released (Rakonjac et al., 2011). 
4.2 Phage display technology 
Because of the nature of the membrane-associated assembly, there is virtually no constrains 
on the size of DNA to be packed in the capsid. Therefore, the bacteriophage vectors are 
useful for construction of genomic, cDNA libraries, and display of peptides or even whole 
proteins on the surface of phage particles. The most prominent example of the protein 
display is construction of libraries of antibody fragments that are proved sources of human 
fragments of monoclonal antibodies (Rakonjac et al., 2011). 
A large number of libraries consisting of variants of peptides are available. They differ by 
number of clones, length of peptide sequences that can be random, or constrained due to the 
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presence of cysteine residues forming a disulfide bond. Although all protein building the 
capsid can be used for display, the most common are libraries utilizing the p3, and the p8 
proteins for presentation of foreign sequences. The pivotal concept is that the peptides 
displayed on the bacteriophage surface, and the DNA sequence coding for that peptide are 
physically linked in one viral particle. This enables easy verification of sequences of 
peptides isolated from the libraries. The libraries are constructed by cloning of 
oligonucleotides encoding for peptides in frame with the gene of the protein used for 
display. Oligonucleotides encoding for peptides can be inserted between sequences 
encoding the leader sequence and the mature p8 (Fig. 2). Peptides are encoded by NNK or 
NNS (where N is A, T, C, G; K is G and T; S is G and C). The cloning can result in all copies 
of the p3 and the p8 expressed as fusion proteins, or only some of the proteins carrying 
peptides. The later can be achieved by introduction into the viral genome of an additional 
copy of the recombinant gene, besides the wild-type gene. The recombinant gene can also be 
delivered to bacteria on a separate genome (a phagemid). Moreover, peptide libraries can be 
expressed as a part of a larger protein scaffold (Uchiyama et al., 2005). 
 
 
Fig. 2. A schematic representation of the constrained peptide library LX-8. Peptides are 
expressed as fusion with the p8 protein. Two genes encoding p8 proteins are present in the 
bacteriophage genome, a wild type (white), and a recombinant one (colour filled). The 
leader sequence is removed during processing of the p8 (Bonnycastle et al., 1996). 
The process of screening of phage-displayed peptide libraries is called a panning. During 
the purification process a peptide library is allowed to interact with screening molecules 
such as for examples antibodies, enzymes, receptors, lectins, or hormones. The target 
receptor can be coated to plastic surfaces, membranes, or used in a solution phase. Affinity 
interactions are basis for most of the screening protocols. Therefore pre-adsorption steps are 
necessary to reduce the numbers of phage clones that bind to other than screening 
molecules, e.g., blocking agents, washing buffer ingredients, and surfaces used for target 
coating. Phages captured via their displayed peptides by the target screening molecule can 
be retained during washing steps. Then, they are amplified in bacteria, and the panning is 
repeated. A resulting pool of phages is enriched in peptides that bind the target molecule 
used for the screening. From such pools single clones can be isolated. Next, the peptides are 
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decoded through DNA sequencing, and then characterised in the phage-displayed 
environment, as well as in a free form (Fig. 3). The screening can also be designed and  
 
 
 
 
Fig. 3. A schematic representation of a biopanning (top). Biotinylated antibodies are 
immobilised in streptavidin-coated wells. The pre-adsorbed library of phage-displayed 
peptides can interact with the immobilised target molecules (see text for more details). 
Immunoblotting and ELISA can be used to analyse phage clones isolated from peptide 
libraries (bottom). The examples from the screening of the LX-8 library with the 14.G2a were 
included (see Horwacik et al., 2007 for more details). Replicas of bacteria infected with phages 
on nitrocellulose membranes were incubated with the 14.G2a antibody and the secondary 
HRP-conjugated antibody, and then developed (bottom left). ELISA with immobilised 14.G2a 
antibody was used to capture specific phage clones. Phage binding was detected with anti-p8 
antibodies. The 0a phage is a negative control (bottom right). 
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conducted on target molecules expressed on the surface of whole cells, or even in mice. 
Applicability of the technique is enormous, and includes new ligand identification, quest for 
agonist and antagonists of receptors, elucidation of binding motifs, epitope mapping, 
analyses of enzymatic activity, new drug and vaccine design (Dudak et al., 2011, Smith & 
Petrenko, 1997). 
4.3 Isolation and optimisation of peptide mimetics of the GD2 ganglioside isolated 
from phage-displayed libraries 
It is a common finding that in addition to binding to original epitopes, antibodies can cross-
react with several antigens (Van Regenmortel, 2001). Phage display techniques were used to 
exploit the molecular mimicry phenomenon to isolate peptide surrogates to tumour-
associated carbohydrate antigens, e.g., Lewis Y (Kieber-Emmons et al., 1999), sialylated 
Lewis a/x (O et al., 1999), and GD3 (Willers et al., 1999). The examples of the peptides 
mimicking the GD2 ganglioside, the antibodies used for their identification, as well as 
references were for convenience collected in the Table 1. Following is the description of their 
antigenic and immunogenic properties, analysed with experimental and computational 
tools, as well as strategies that were used to improve their mimicry. 
 
Antibody Peptide name Peptide sequence Reference 
ME36.1 P9 
P10 
P10s 
 
LDVVLAWRDGLSGAS 
GVVWRYTAPVHLGDG 
WRYTAPVHLGDG 
Qiu et al., 1999 
Monzavi-Karbassi et al., 2007 
Ch14.18 MD 
MA 
C3 
CDGGWLSKGSWC 
CGRLKMVPDLEC 
CGRLHLVPDLEC 
Förster-Waldl et al., 2005 
Bleeke et al., 2009 
14.G2a 47 
47-LDA 
EDPSHSLGLDVALFM 
EDPSHSLGLDAALFM 
 
Bolesta et al., 2005 
14.G2a 94 
94-12-F/W-AAEGD
RCNPNMEPPRCF 
RCNPNMEPPRCWAAEGD
Horwacik et al., 2007 
Horwacik et al., 2011 
Table 1. Examples of mimicking peptides isolated with the anti-GD2 ganglioside 
monoclonal antibodies. 
4.3.1 Peptides isolated with the ME36.1 antibody 
The ME36.1 monoclonal antibody displays reactivity with the gangliosides GD2 and GD3. 
The antibody was used to screen the 15-mer library build with the fUSE5 vector. Qiu et al. 
reported in 1999 results of a panning of the library with the ME36.1 antibody. 16 peptides 
were isolated. Sequence analysis revealed presence of mainly unique sequences, which 
indicated that many peptides could mimic the GD2 ganglioside binding to the ME36.1. 
Interestingly, some similarities between the peptides isolated with the ME36.1 and the BR55-
2 (binding Lewis-Y) were found, i.e., presence of WRY and AP sequences in the peptide P10 
(GVVWRYTAPVHLGDG), and WRDG in the peptide P9 (LDVVLAWRDGLSGAS) that is 
similar to YRGD found in a peptide isolated with the BR55-2. 
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ELISA was applied to compare ganglioside reactivity of IgM in sera samples of non-
immunised animals, and animals immunized with the P10. For vaccinations the P10 was 
presented as multiple antigenic peptides of 8 peptide clusters (MAP), injected 
intraperitoneally (i.p.) with QS-21 adjuvant. The obtained results suggested that the P10 
might induce serum IgM antibodies reactive with multiple gangliosides. The analysis of 
data comparing dilutions yielding half-maximal binding to different gangliosides showed 
that the peptide could functionally mimic GD1b, GD1a, GD3, and only to a lesser extent 
GD2 and GM2. The finding was supported with molecular modelling approach revealing 
that the P10 interacts with the ME36.1 with only two hydrogen bonds (with Tyr33 and 
Ser100 from the heavy chain) in common, as compared to the GD2 ganglioside binding 
network to the antibody (i.e., with Tyr33, His35, Asp50, Asn52, Asn59, and Ser100 from the 
heavy chain, and Tyr93 from the light chain). 
In efforts to improve the immunological mimicry of the GD2 ganglioside, a shorter peptide 
missing the N-terminal GVV sequence was designed (P10s). It showed a rise in numbers of 
bonds involved in the ME36.1 interactions (Tyr33, Asp50, Asn59, and Ser100 from the heavy 
chain, and Tyr93 from the light chain). Additionally, immunisation with the P10s induced 
IgM in sera with augmented reactivity toward GD2, GD3, GM2 (as compared to the P10). 
Moreover, the sera collected from mice immunised with the P10s showed higher binding to 
the GD2 ganglioside positive MCF7 human breast cancer cells, and WM793 melanoma cells, 
as compared to sera from mice immunised with the P10 (Monzavi-Karbassi et al., 2007). 
4.3.2 Peptides isolated with the ch14.18 antibody 
Förster-Waldl et al. published in 2005 results from their panning experiments (Förster-Waldl 
et al., 2005). The group screened a peptide phage-displayed library expressed in the context 
of the p3, and constrained by presence of additional cysteines at N and C termini of the 
peptides. The authors reported isolation of 13 different phage-displayed peptides that 
specifically recognized the ch14.18 antibody, in contrast to wild type phages. An isotype 
control antibody (cetuximab) was included in the binding assays. In most of the clones R is 
present in the position 2 of the decamers flanked by cysteines, hydrophobic V, L, or M are in 
the positions 5 or 6, and acidic D or E occupies the position 10. The antigenicity of the 
phage-expressed peptides was positively verified with application of a competitive ELISA, 
to measure their specific binding to the ch14.18 against simultaneously added GD2 
ganglioside. Two peptide sequences were chosen for further studies, i.e., the MD peptide 
(CDGGWLSKGSWC) and the MA peptide (CGRLKMVPDLEC). 
In the next step, a computer model of interactions between the ch14.18 and the GD2 
ganglioside, or the two peptides was built. The peptide MD was shown not to block the 
binding site as effectively as the peptide MA. In 2006, additional in silico data were 
published by Fest et al. Eight residues of the ch14.18 were found to interact with both the 
two peptides and the GD2 ganglioside, i.e., Tyr37, His54, Ser96, Val99, Pro100, Leu102 from 
the light chain, as well as Gly98 and Gly100 from the heavy chain. Also, dissociation 
constants were determined with surface plasmion resonance (Fest et al., 2006). 
Immunogenicity of the both peptides was investigated after their conjugation to KLH. In the 
sera of mice immunised with both peptide conjugates antibodies of IgM and IgG isotypes 
recognising the GD2 ganglioside were raised, as detected with ELISA. The sera samples also 
bound specifically to the GD2 positive M21 melanoma cells (Reimer et al., 2006). 
The MA sequence was recently improved, as reported by Bleeke and co-authors. This was 
achieved after another two rounds of screenings with the ch14.18 of synthetic sub-libraries, 
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produced on a solid support, and containing systematic alterations based on the MA 
sequence (Bleeke et al., 2009). The experiments yielded a new mutated sequence C3 
CGRLHLVPDLEC with significantly improved binding to the ch14.18, as determined with 
dot blot and surface plasmion resonance measurements using BIACORE. 
4.3.3 Peptides isolated with the 14.G2a antibody 
Bolesta and co-authors reported screening with the 14.G2a of 15-mer library of linear 
peptides, fused with the p8 protein (in the f88-4 vector). 6 peptides were isolated, and 
shown to bind to the 14.G2a antibody by ELISA. Moreover, all the peptides in the free form 
competed for binding to the 14.G2a with the GD2 ganglioside present on a human 
neuroblastoma cell line IMR-32 (Bolesta et al., 2005). Importantly, three peptides (47, 9, and 
51) cross-reacted with GD2 ganglioside binding antibodies from a serum sample of a 
neuroblastoma patient. Competition experiments between peptides 47, 9, and 51 showed 
that they mimic an overlapping epitope of the GD2 ganglioside. 
The peptide 47 (EDPSHSLGLDVALFM) with highest score in the competition tests was 
chosen for further optimisation. Also here, molecular modelling was conducted to build a 
model of interactions between the 47 peptide, and the antigen binding site of the 14.G2a. 
Additionally, alanine scanning enabled identification of amino acid residues pivotal for the 
observed binding. As a result, the LGLDVALFM sequence was found essential for the 
interactions with the 14.G2a. More importantly, substitution of V with A yielded the 47-LDA 
(EDPSHSLGLDAALFM) peptide that was 2-fold more effective than the original 47, in the 
competition assays against the IMR-32 cells. 
Based on the findings, the 47-LDA peptide, and two universal T helper epitopes (PADRE, 
and P18MN epitope from envelope protein of HIV-1 isolate MN) were encoded in a DNA 
vaccine, constructed in the pNGVL-7 vector that contained the tissue plasminogen activator 
secretory signal sequence. The vaccine induced anti-GD2 ganglioside IgG antibodies in 
BALB/c mice. The level of GD2 ganglioside cross-reactive antibodies was further increased 
with prime-boost strategy that utilised first the 47-LDA construct, and then the GD2 antigen 
administered in incomplete Freund’s adjuvant. The sera samples obtained from 
immunisations with the DNA construct alone, as well as in combination with the GD2 
ganglioside boost, mediated complement dependent lysis of the GD2 positive IMR-32 
neuroblastoma, and HT-144 melanoma cells (Bolesta et al., 2005). 
Yet another 5 sequences binding to the 14G2a antibodies were isolated, but this time from 
the constrained library LX-8 (Horwacik et al., 2007). The library displays 12-amino acid 
peptides. Their structure is constrained by the presence of two cysteines at the positions 2 
and 11. Binding motifs were identified through sequence comparisons. LTG or LSG motifs 
are present in the centre in 3 of 5 isolated peptides. D or N is present in the position 3 of 4 
peptides, while P occupies the position 4 in 2 peptides, and L is present in the positions 9 (in 
2 peptides), and 10 (in 3 peptides). Finally, S occupies the position 12 in 2 peptides. All five 
peptides were shown to mimic the GD2 ganglioside, as analysed by ELISA. The peptides 
presented in the phage-bound form, as well as the free synthetic form competed for binding 
to the 14.G2a with the GD2 ganglioside present on the IMR-32 cells (Fig. 4). More 
importantly, the presence of the disulfide bond, formed by the cysteines 2 and 11, is pivotal 
for the observed mimicry of the GD2 ganglioside for all 5 constrained peptides. 
To further characterise antigenic features of the peptides, we analysed reactivity of 3 
peptides (65, 85, 94) with other than the 14.G2a mouse monoclonal antibodies that had been 
raised against gangliosides, i.e., the anti-GD2 antibody 126 (IgM), anti-GD2 antibody ME361-
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S2A (IgG2a), and the anti-GD3 antibody ME3.6 (IgG3). But, the peptides did not bind to 
them, which highlights the fact that peptide-carbohydrate mimicry is observed in the 
context of a given receptor (the 14.G2a in this case). Additionally, the peptides were shown 
to occupy overlapping binding sites on the 14.G2a. This finding was supported by in silico 
models of interactions of the peptides with the Fab fragment of the 14.G2a (Horwacik et al., 
2011). 
 
 
Fig. 4. The peptide 94 can compete with the GD2 ganglioside present on IMR-32 
neuroblastoma for biding to the 14.G2a (as analysed by flow cytometry). The inhibitory 
effect is significantly improved for modified peptides 94-AAEGD and 94-12-F/W-AAEGD. 
No inhibition was detected with a control peptide T2. The pool of GD2-positive IMR-32 cells 
was determined by comparison of cells stained with the 14.G2a and the secondary FITC-
conjugated (Fab’)2 fragments specific to mouse immunoglobulins (14.G2a), and cells stained 
only with the secondary antibody fragments (II). 
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The peptide 94 (RCNPNMEPPRCF) was chosen for further analysis and optimisation of the 
binding to the 14.G2a. Alanine scanning, replacement analysis, and truncation experiments 
allowed to elucidate structure-activity relationships that are the basis for the observed 
mimicry of the GD2 ganglioside by the peptide 94. The experiments showed that C2, N3, 
M6, E7, C11 are indispensable for the observed binding, as their substitution by alanine 
resulted in a complete loss of the 14.G2a binding. A new peptide with better binding to the 
antibody was identified by replacement of F at the position 12 with W. The antigenicity was 
even further improved with extension of the C terminus with the AAEGD sequence, taken 
from the N terminus of the viral coat protein p8 (Horwacik et al., 2011). The peptide 94-12-
F/W-AAEGD (RCNPNMEPPRCWAAEGD) was the best in the competition assay against 
the IMR-32 cells, and showed 18-fold decrease in the measured IC50 values (half maximal 
inhibition concentration), as compared to the original 94 sequence (Fig. 4). The obtained 
peptides are currently being further analysed to verify relationships between their 
antigenicity and immunogenicity. 
4.4 Vaccination using the GD2 mimetics in preclinical settings 
Many of the isolated peptides mimicking the GD2 ganglioside were tested in pre-clinical 
experiments, using several modes of delivery (e.g., DNA vaccines, dendritic cell-based 
vaccines, KLH-conjugated peptides) with application of syngeneic (Bleeke et al., 2009; Gil et 
al., 2009; Kowalczyk et al., 2007; Wierzbicki et al., 2008; Wondimu et al., 2008), and 
heterotransplant mouse models (Bolesta et al., 2005). 
4.4.1 Tests of GD2 ganglioside mimics in melanoma models 
Sera were collected from animals immunised with the 47-LDA DNA vaccine/GD2 
ganglioside boost. Therapeutic efficacy of purified fractions of mouse IgG antibodies 
containing the GD2 ganglioside cross-reactive antibodies was tested in a heterotransplant 
model, based on s.c. injection of a human MV3 melanoma (106 cells). Multiple i.v. injection 
of the antibodies were conducted, starting 3 days after the tumour challenge. They lead to 
significant decrease in tumour growth in the group of animals treated with the GD2 
antibodies, as compared to control mice treated with murine IgG. However, none of the 
mice on therapy with the GD2 ganglioside specific antibodies showed a complete resolution 
of the melanoma tumours (Bolesta et al., 2005). 
Similar indications of anti-melanoma efficacy of vaccines based on the GD2 mimicking 
peptides were gathered on a syngeneic model with s.c. injections of GD2 ganglioside 
positive melanoma cells D142.34 to C56BL/6 mice. Peptide vaccines containing the P9, or 
the P10 conjugated to KLH, or in the form of MAP were delivered s.c. with QS-21 adjuvant. 
GD2 ganglioside specific antibodies were raised by the immunisations with both peptides, 
as compared to control group injected with an unrelated peptide. In animals that received 
vaccines with the peptides, DTH reactions were detected 48, and 72 h after administration of 
irradiated D142.34 cells, in contrast to injections with GD2 ganglioside negative B78.H1 
melanoma cells. In a prophylactic setting, the vaccines with the P10 were more effectively 
inhibiting s.c. growth of the D142.34 cells than the vaccines with the P9, as evidenced by 
tumour volume and weight measurements. Moreover, P10-KLH vaccinations in a 
therapeutic setting, starting 10 days after challenge with the D142.34 cells, delayed growth 
of tumours, as compared to control peptide vaccination. Although, the statistical 
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significance could not be achieved in the therapeutic setting, the data emphasise that 
induction of protective responses targeting the melanoma cells with active immunisation 
with the GD2 mimicking peptides was possible (Wondimu et al., 2008). 
4.4.2 Tests of GD2 ganglioside mimics in syngenic neuroblastoma models 
A syngeneic mouse model based on injections of NXS2 cells that show heterogeneous 
expression of the GD2 ganglioside to mice of A strain was reported in 1997 (Lode et al., 
1997). The model was applied to test DNA constructs bearing Ig leader sequence, T helper 
epitope for HIV-1 envelope protein, and MA, or MD epitopes separated with flexible 
glycine-serine linkers in the pSA vector. The construct was used for oral mice immunisation 
after transfection to attenuated Salmonella typhimurium SL7207. The regiment used in a 
prophylactic setting was shown to significantly reduce spontaneous liver metastases, as 
determined about a month after removal of s.c. NXS2 tumors. This was correlated with 
induction of anti-GD2 antibodies responses in sera of mice vaccinated with MA or MD, as 
well as with significant increase in activity of spleen derived NK cells from pSA-MD 
immunised mice. The later was evidenced by ability of the NK cells to lyse YAC-1 cells, but 
not NXS2 cells. However, the effect was only observed with the effector cells co-cultured 
with irradiated NXS2. Additionally, orally delivered Salmonella typhimurium SL7207, 
carrying the empty vector pSA, was shown to be an effective adjuvant to establish GD2 
ganglioside specific antibodies, and NXS2 protective immune responses in A mice, with 
protein vaccines containing the peptides MD and C3 conjugated to KLH, and absorbed on 
alum. No CD8+ T cell immune responses were observed with the DNA vaccines. No 
experiments in therapeutic setting were described (Bleeke et al., 2009; Fest et al., 2006). 
On the contrary, sequence of the peptide 47-LDA delivered in the form of DNA construct 
effectively induced antibody and cell mediated immune responses that inhibited growth of s.c. 
NXS2 tumour in A mice in therapeutic setting. Kowalczyk and co-authors showed that 
protection against tumour challenge with NXS2 cells required both innate (NK cells), and 
adoptive cell-mediated immunity (CD4+ and CD8+ T cells). Furthermore, administration of 
plasmids encoding IL-15, and IL-21 cytokines together with the 47-LD construct markedly 
enhanced the tumour protective immunity. In the group of animals that were treated with the 
combined immunisation regiment, delivered from 1 day after s.c. NXS2 challenge, 6 of 8 
animals remained tumour-free more than 90 days. The inclusion of the plasmids encoding IL-
15, and IL-21 in the vaccination protocol, significantly increased levels of GD2 ganglioside 
cross-reactive IgG in sera of mice, as well as CDC and ADCC against NXS2 cells. More 
importantly, re-challenge experiment in the group of 8 animals that remained tumour free, 
showed that all the animals survived additional 90 days, in contrast to control mice that 
developed tumours by day 30. Finally, adoptive transfer of CD8+ T cells from 47-LDA 
vaccinated and cured mice to NXS2-challenged mice, significantly influenced tumour control, 
as most of the mice survived tumour-free for more than 90 days (Kowalczyk et al., 2007). 
The CD8+ T cell responses induced with the 47-LDA construct were further investigated. 
Interestingly, they were shown to be MHC class I restricted to syngeneic neuroblastoma 
cells (NXS2, Neuro2a), but independent of the GD2 ganglioside expression. This suggested 
that than GD2 vaccine induced responses cross-reactive with other the GD2 antigen present 
on neuroblastoma cells. The hypothesis was confirmed with experiments showing that the 
14G2a cross reacts with a 105 kDa protein, ALCAM/CD166 (activated leukocyte cell 
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adhesion molecule). When the expression of CD166 was silenced using specific shRNA in 
Neuro2a, the cells were no longer killed by CD8+ T cells from mice immunised with the 47-
LDA construct. Additionally, such cells induced progressive growth of s.c. tumours in mice, 
despite of the combined immunisation with the 47-LDA, IL-15, IL-21 constructs that 
preceded the challenge. This finding shed new light on application of peptide mimicking the 
GD2 ganglioside. Here the 47-LDA was shown to induce responses to conformation-
dependent epitope of CD166 protein (Wierzbicki et al., 2008). 
In the following report in 2009, the 47-LDA mimotope was expressed as a fusion protein 
with the mouse IgG2a Fc region, and used for vaccination based on dendritic cells (DC). 
Targeting the mimotope vaccine to activating Fc receptors of DC allowed for selective 
expansion of adoptively transferred CD8+ T in NXS2-tumour bearing syngeneic mice. Anti-
tumour responses were also observed with virotherapy, after delivery of recombinant 
oncolytic vaccinia virus expressing the 47-LDA- Fc2a fusion protein (Gil et al., 2009). 
5. Conclusion 
Tumour associated-carbohydrate antigens are highly over expressed in tumour cells, and 
therefore are attractive targets for both passive and active immunization approaches. Both, 
mimicking peptides and anti-idiotypic antibodies can functionally mimic carbohydrates, 
including the GD2 ganglioside. Furthermore, such surrogate antigens often induce humoral 
and cellular immune responses, which the carbohydrate itself is usually unable to induce. 
Peptides are easier to manufacture and modify than carbohydrates. Additionally, they can 
be used to manipulate immune responses, i.e., to present cryptic epitopes, and to break 
tolerance by focusing the response on critical epitopes delivered in a different molecular 
environment. The data on application of the molecular mimicry to target the GD2 
ganglioside adds knowledge on structural-activity relationships of such mimicking 
peptides, and anti-idiotypic antibodies, and correlates of their immunogenicity. This extends 
our understanding of vaccine design in cancer. Hopefully, this will boost research on future 
vaccines targeting neuroblastoma. 
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